Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Rating) in a research report sent to investors on Friday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 0.0 %

BTX opened at $0.21 on Friday. The firm has a fifty day moving average of $2.00. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC raised its position in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX – Get Rating) by 20.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,459,626 shares of the company’s stock after acquiring an additional 243,826 shares during the period. Renaissance Technologies LLC owned approximately 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 as of its most recent filing with the SEC.

About Brooklyn ImmunoTherapeutics

(Get Rating)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.